Skip to main content

2026-05322

Proposed Rule

Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis

In Committeehealthcare

Introduced: March 18, 2026

Progress

Summary

The Food and Drug Administration (FDA) is proposing to require the filing of a premarket approval application (PMA) for blood irradiators intended to irradiate intraoperatively salvaged blood for cancer patients undergoing surgery to assist in prevention of metastasis, which are unclassified, preamendments devices. FDA is summarizing its proposed findings regarding the degree of risk of illness or injury designed to be eliminated or reduced by requiring the devices to meet PMA requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the benefits to the public from use of the devices.

How This Affects You

Sign up to see how this bill affects you personally

Already have an account? Log in

View on Federal Register

Get personalized insights on this bill

CivicRadar tells you exactly how government actions affect your life based on your location, interests, and profession.